HeartFlow
Mountain View, California, USA
AI-powered coronary artery disease diagnostic platform with IPO in 2025
Source: Digital.Health
Digital.Health provided this information. To learn more and get deep data on digital health companies, please visit them here.
Visit Digital.Health →How We Help
Problem Statement
To transform coronary artery disease (CAD) from a leading cause of death into a manageable condition.
Core Technology
AI-powered
Key Differentiators
AI-driven platform, non-invasive solution for CAD, creates personalized 3D models of coronary arteries, helps diagnose CAD, assess blood flow, quantify and characterize plaque, extensive clinical evidence, over 600 peer-reviewed publications.
Clinical Focus
Coronary Artery Disease (CAD)
Target Customers
Hospitals and healthcare providers
Product Stage
GA
Company Info
- Business Model
- SaaS
- Founded
- 2007
- Total Funding
- 936,000,000
Categories
Technologies
Clinical & IP
Clinical Validation
Extensive clinical evidence with over 600 peer-reviewed publications.
MedStartr Index Score
?What do you think of HeartFlow?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.